

Margaretha Rudas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/606332/publications.pdf>

Version: 2024-02-01

41
papers

1,469
citations

471509

17
h-index

361022

35
g-index

42
all docs

42
docs citations

42
times ranked

2125
citing authors

#	ARTICLE	IF	CITATIONS
1	Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response. <i>Clinical Cancer Research</i> , 2022, 28, 697-707.	7.0	17
2	A risk stratification algorithm for lesions of uncertain malignant potential diagnosed by vacuum-assisted breast biopsy (VABB) of mammographic microcalcifications. <i>European Journal of Radiology</i> , 2021, 135, 109479.	2.6	7
3	Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34. <i>British Journal of Cancer</i> , 2021, 124, 1795-1802.	6.4	3
4	The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8. <i>Clinical Cancer Research</i> , 2021, 27, 5931-5938.	7.0	1
5	The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial. <i>European Journal of Cancer</i> , 2020, 134, 99-106.	2.8	29
6	Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor-Positive Early Breast Cancer: Results from the ABCSG Trial 5. <i>Clinical Cancer Research</i> , 2020, 26, 5682-5688.	7.0	4
7	Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4682-4687.	7.0	22
8	Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34). <i>European Journal of Cancer</i> , 2020, 132, 43-52.	2.8	24
9	Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer. <i>BMC Cancer</i> , 2019, 19, 695.	2.6	4
10	PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [18F]FDG PET/CT. <i>Molecular Imaging and Biology</i> , 2019, 21, 991-1002.	2.6	8
11	Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2- Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. <i>Clinical Cancer Research</i> , 2019, 25, 3865-3872.	7.0	54
12	Differential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast Cancer. <i>Cancer Investigation</i> , 2018, 36, 378-388.	1.3	8
13	Ki67 to predict RCB0/I after neoadjuvant chemotherapy and endocrine therapy in HER2- breast cancer patients from ABCSG 34.. <i>Journal of Clinical Oncology</i> , 2018, 36, 589-589.	1.6	1
14	Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 3676-3683.	7.0	29
15	A simple classification system (the Tree flowchart) for breast MRI can reduce the number of unnecessary biopsies in MRI-only lesions. <i>European Radiology</i> , 2017, 27, 3799-3809.	4.5	59
16	The breast lesion excision system (BLES) under stereotactic guidance cannot be used as a therapeutic tool in the excision of small areas of microcalcifications in the breast. <i>European Journal of Radiology</i> , 2017, 93, 252-257.	2.6	11
17	Independent validation of stromal uPA in archived tumor samples from the prospectively randomized ABCSG8 trial to provide level 1b evidence for a prognostic value of uPA immunohistochemistry in endocrine-treated postmenopausal breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 536-536.	1.6	7
18	Diffusion-weighted MRI of breast lesions: a prospective clinical investigation of the quantitative imaging biomarker characteristics of reproducibility, repeatability, and diagnostic accuracy. <i>NMR in Biomedicine</i> , 2016, 29, 1445-1453.	2.8	46

#	ARTICLE	IF	CITATIONS
19	Association of TP53 mutations with TP53 codon 72 polymorphism and outcome in triple-negative breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 70-75.	0.5	0
20	Circulating tumor cells as an early detection tool for BRCA positive women?. <i>Journal of Clinical Oncology</i> , 2016, 34, e13025-e13025.	1.6	0
21	PIK3CA mutational status and correlation with tumor glycolysis imaged with [18F]FDG PET/CT in early primary ER+ / HER2- breast cancer patients: A feasibility study.. <i>Journal of Clinical Oncology</i> , 2016, 34, e12050-e12050.	1.6	0
22	Multiparametric MR Imaging with High-Resolution Dynamic Contrast-enhanced and Diffusion-weighted Imaging at 7 T Improves the Assessment of Breast Tumors: A Feasibility Study. <i>Radiology</i> , 2015, 276, 360-370.	7.3	44
23	Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy. <i>Clinical Breast Cancer</i> , 2015, 15, 505-511.	2.4	4
24	Diagnostic accuracy of 18F-FDG PET/CT compared with that of contrast-enhanced MRI of the breast at 3 T. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1656-1665.	6.4	22
25	Activity of T-DM1 in Her2-positive breast cancer brain metastases. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 729-737.	3.3	103
26	Mineral oil in human tissues, Part II: Characterization of the accumulated hydrocarbons by comprehensive two-dimensional gas chromatography. <i>Science of the Total Environment</i> , 2015, 506-507, 644-655.	8.0	50
27	Prognostic impact of breast cancer (BC) subtype in elderly patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20536-e20536.	1.6	0
28	Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer. <i>Breast Care</i> , 2014, 9, 6-6.	1.4	8
29	Antiestrogenic effects of the fetal estrogen estetrol in women with estrogen-receptor positive early breast cancer. <i>Carcinogenesis</i> , 2014, 35, 2447-2451.	2.8	21
30	Mineral oil in human tissues, Part I: Concentrations and molecular mass distributions. <i>Food and Chemical Toxicology</i> , 2014, 72, 312-321.	3.6	77
31	Alleviation of Brain Edema and Restoration of Functional Independence by Bevacizumab in Brain-Metastatic Breast Cancer: A Case Report. <i>Breast Care</i> , 2014, 9, 134-134.	1.4	25
32	Predicting local recurrence using PAM50 in postmenopausal endocrine responsive breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1008-1008.	1.6	5
33	Association of TP53 codon 72 polymorphism with TP53 mutation in triple-negative breast cancer (TNBC) patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1130-1130.	1.6	1
34	Diffusion-weighted imaging using ADC mapping as an imaging biomarker for breast cancer invasiveness.. <i>Journal of Clinical Oncology</i> , 2013, 31, 11093-11093.	1.6	0
35	Low HER2-expression to predict impaired activity of endocrine therapy in patients with estrogen-receptor (ER) positive metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 573-573.	1.6	7
36	BRCA-1 promotor methylation as predictor of benefit from adjuvant CMF in triple-negative breast cancer not responsive to taxane-based neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2013, 31, 148-148.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Decentral gene expression analysis for ER+/Her2 ⁺ breast cancer: results of a proficiency testing program for the EndoPredict assay. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 460, 251-259.	2.8	88
38	Hybrid PET-MRI of the breast: A promising tool for the characterization of breast tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10570-10570.	1.6	1
39	Impact of the EndoPredict-clin score on risk stratification in ER-positive, HER2-negative breast cancer after considering clinical guidelines.. <i>Journal of Clinical Oncology</i> , 2012, 30, 542-542.	1.6	1
40	A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors. <i>Clinical Cancer Research</i> , 2011, 17, 6012-6020.	7.0	597
41	Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy. <i>Clinical Cancer Research</i> , 2008, 14, 1767-1774.	7.0	81